Professor John McMurray discusses DAPA-CKD and what insights it provides into the cardiorenal protection seen with dapagliflozin (Farxiga) use in the landmark trial.
An analysis comparing the results of patients with and without cardiovascular disease at baseline from within the landmark DAPA-CKD trial is providing clinicians with further evidence of the cardioprotection seen with dapagliflozin (Farxiga).
Just a few months after initial results were presented at ESC 2020, the latest analysis concluded the effects of dapagliflozin seen in DAPA-CKD, which includes reductions in risk of kidney failure and risk of worsening heart failure, were consistent regardless of a patient’s history cardiovascular disease.
Presented by John McMurray, MD, professor at the University of Glasgow, at the American Heart Association (AHA) Scientific Sessions 2020, results of the DAPA-CKD analysis build on the previously established safety and efficacy profile of the SGLT2 inhibitor. In the original trial, dapagliflozin was associated with a reduction in risk of the primary end point of preventing worsening kidney function or death from kidney disease or cardiovascular disease by 39%—with reductions of 36% and 50% in patients with and without diabetes, respectively.
In the present analysis, stratification by cardiovascular history at baseline indicated the effect of dapagliflozin on the primary endpoint, cardiovascular disease/heart failure, all-cause mortality were maintained (P for interaction >.05 for all).
For more on the results of this analysis and what it tells clinicians about dapagliflozin in patients with chronic kidney disease and a history of cardiovascular disease, Practical Cardiology invited McMurray to take part in a special edition AHA 2020 House Call.
This study, “Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD),” was presented at AHA 2020.